Impact of Routine Pediatric PCV13 on the Incidence and Severity of Invasive Pneumococcal Disease in Adults in
Background. Monitoring the incidence and severity of disease due to varied pneumococcal (Pn) serotypes (STs) over time is important in assessing the benefit of Pn vaccines. We describe changes in adult IPD after the 2010 introduction of routine infant PCV13 in Ontario, Canada (PCV13 is funded only for immunocompromised adults ≥50 years as of 2015).
Methods. TIBDN has conducted population-based surveillance for IPD in Toronto/Peel, Canada (pop 4.3M) since 1995. Cases are reported to a central office; one isolate/case is serotyped. Demographic and clinical data are collected by chart review and patient/family physician interview.
Results. Conclusion. In our population, with infant but no routine adult PCV13, the incidence of adult IPD appears to have stabilized, with PCV13 ST strains contributing 37% of IPD. Case fatality has decreased; ICU admission increased. Adult vaccination may be required to further reduce PCV13 ST infections. 
A Dynamic Modeling Study of the Effect of Introducing a New Higher
Methods. An age-structured dynamic transmission model of Streptococcus pneumoniae before and after PCVs introduction was developed. The model was fit to longitudinal Active Bacterial Core surveillance (ABCs) data (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) in the United States on distribution and cases of IPD, as well as population level prevalence and serotype distribution data. It was assumed that total S. pneumoniae carriage remains constant over time, with full carriage replacement within four years of introduction of any PCV. Two alternative new PCVs with differing IPD coverage are tested with an introduction date of 2024.
Results. When compared with continuing vaccination of infants with PCV13, 10 years after a new PCV is introduced (2,034) cases of IPD are substantially reduced (shown in the table below). Broader serotype coverage leads to greater reductions in IPD. The greatest IPD reduction occurs in the directly vaccinated infant groups, however similar reductions are also observed in the unvaccinated elderly population due to herd protection. Methods. We adapted a previously published forecasting model to estimate the reduction in OM cases in Canada since the introduction of PCVs in all routine provincial programs in 2005 through 2015 (the last year complete data were available). The impact of PCV on OM was modeled and compared with pre-PCV incidence to estimate net impact of the vaccine. We assumed that 90% of OM episodes were treated with an initial Abx given routine practice. All data were sourced from the published literature.
Conclusion. A new, higher valent PCV given to infants in the United

Modeling Reductions in Antibiotic Prescriptions due to Otitis Media in Canada as a Result of Pneumococcal Conjugate Vaccination
Results. Over 10 years, PCVs were estimated to avert 3.7 million cases of OM in Canada. This corresponded to an estimated reduction of 3.3 million Abx, or 0.96 Abx avoided per infant vaccinated with PCV.
Conclusion. PCVs have had a significant public health impact on reducing the burden of disease and Abx. While most of the PCV impact on reduction of Abx is due to reduction in OM cases, additional Abx reduction from prevention of other invasive and noninvasive pneumococcal diseases is of importance. Further research is necessary to understand the additional net benefit of reducing antibiotics across the disease spectrum given that reductions in net prescribing could avert further downstream resistance by other pathogens. 
